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Abstract
Traditional liposomes degrade into lower-order micelles when PEGylated to even minor degrees 
(6–7 mol %) and therefore can offer only limited steric exclusion against opsonization during in 
vivo delivery. In this work, we present for the first time a liposome coated exclusively by 
PEGylated phospholipids, utilizing lipid-coated calcium phosphate (CaP) cores of diverse sizes 
(10–15 nm, 30–40 nm) as well as varying polyethylene glycol (PEG) chain lengths (350–5000 
Da). Such fully-PEGylated liposome calcium phosphate (LCP) particles exhibit a PEG chain 
length-dependent circulation longevity and robust immune evasion, while facilitating both strong 
accumulation within solid tumors upon intravenous injection and a more rapid and extensive 
lymphatic drainage upon subcutaneous administration. Further, these fully-PEGylated liposomes 
remain amenable to active targeting strategies which facilitate improved degrees of focused 
distribution and nanoparticle uptake, represent a lipid packing density commensurate with the 
formation of a lipid bilayer, and avoid use of scale-limited physical resuspension methods. We 
expect such improved delivery properties to translate into improved therapeutic safety and efficacy 
for a variety of systemic and lymphatic diseases.
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1. INTRODUCTION
Of the advances made upon liposomal platforms for drug and gene delivery over the last 
half-century, surface PEGylation remains one of the most foundational in conferring 
clinically meaningful effects.1,2 The ability to expand circulation longevity of liposomes 
through a decrease in opsonin-mediated immune cell recognition has allowed for a relevant 
exploitation of the enhanced permeation and retention (EPR) effect in cancer therapy.3–6 
However, due to strong surfactant forces directed upon a PEGylated liposome surface, 
further compounded by the relatively weak hydrophobic exclusion effect which supports 
formation of a lipid bilayer around an aqueous core, PEGylation at greater than roughly 6–7 
mol % lipids serves to dissolve the lipid bilayer structure, producing lower-order micelles 
which possess more thermodynamically stable hydrophobic cores.7 Such limitations in 
density likely contribute to the rapid clearance of such nanoparticles compared to other 
advanced formulations by the immune system and may contribute to an acquired immune 
response upon subsequent injections, in particular toward the comparatively diverse 
chemical structure of the polyethylene glycol (PEG)-lipid conjugation site.8,9 Therefore, 
effective means by which to PEGylate liposomes to higher densities remain desirable in the 
development of advanced nanomedicines.
A series of recently developed liposomal formulations7,10,11 perform in such a manner by 
means of what is known as the “supported bilayer phenomenon”. Specifically, should a 
liposome possess not an aqueous core, but a solid, stable, and molecularly interactive core 
material, the lipid bilayer will remain intact even under the forces conferred by increasing 
PEGylation density, allowing a progression toward the steric limits of PEGylation for each 
respective formulation.7 Considerable benefit has been wrought from the liposome calcium 
phosphate (LCP) formulation method in particular, including a selective and ApoE-
dependent tropism of LCP for the hepatocytes of the liver at such high PEGylation,12 as well 
as notable siRNA-mediated gene silencing efficacy in the systemic treatment of various 
cancers.13,14 However, despite high (20 mol %) PEG density, previously published work 
often describes marginal circulation longevity for LCP, in particular as the macromolecular 
complexity of the encapsulated cargoes increases.12,15 Further, though cells possess reliable 
Haynes and Huang Page 2













intrinsic means by which to overcome the high-calcium conditions elicited through LCP-
mediated endosome escape,16 cationic lipid-mediated toxicity remains a concern in many 
nanoparticle formulation strategies.3,17 LCP also has been shown to facilitate endosomal 
release even in the absence of cationic lipids through a number of coordinated 
mechanisms.12,18,19 Thus, an enhanced stealth property is expected to improve control over 
nanoparticle distribution in vivo, contributing to the therapeutic potential of such delivery 
systems overall.
Herein, we present for the first time a liposome coated on its outer leaflet exclusively by 
PEGylated phospholipids and representing a lipid packing density at the level of both inner 
and outer leaflets commensurate with a traditional lipid bilayer. These particles can be 
formulated with a variety of calcium phosphate (CaP) core sizes (10–15 nm, 30–40 nm) and 
outer-leaflet polymer chain lengths (350–5000 Da) through a scalable resuspension process 
as well, avoiding the high-energy conditions required under such means for traditional 
liposome formulations. Such fully-PEGylated liposomes exhibit a chain length-dependent 
circulation longevity and an evasion of uptake in traditional organs of nanoparticle clearance 
(liver, kidneys, spleen), while maintaining passive tropism toward primary hepatocytes over 
Kupffer cells within the liver.12 In particular, due to their improved kinetic profile in vivo, 
these fully-PEGylated liposomes show both a strong accumulation within solid tumors upon 
intravenous injection and a more rapid and extensive local lymphatic access after 
subcutaneous administration. Given focused systemic distribution and capable cell 
internalization through traditional active targeting, these kinetically and distributively 
improved liposomes exhibit strong potential for the treatment of a variety of systemic and 
lymphatic diseases.
2. MATERIALS AND METHODS
2.1. Materials
1,2-Distearoyl-sn-glycero-3-phosphatidylethanolamine¬-N-[carbonyl-methoxy(polyethylene 
glycol)-2000] (DSPE-PEG2000) was purchased from NOF corporation (Tokyo, Japan). 1,2-
Dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG2000-anisamide (AA), DSPE-
PEG2000-galactose (GAL), and DSPE-PEG2000-mannose (MAN) were synthesized 
following previously described protocols15,20,21 and analyzed via NMR using a Varian Inova 
400 MHz NMR spectrometer (Palo Alto, CA). All other lipids, including 
nitrobenzoxadiazolyl (NBD)- and fluorescein isothiocyanate (FITC)-modified DOPA, 
DOPC, and DSPE-PEG (referenced in the text as NBD-OPA, NBD-OPC, and DSPE-PEG-
FITC, respectively), were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 
Ultracentrifuge tubes were purchased from Beckman Coulter (Indianapolis, IN). 177Lu was 
purchased from PerkinElmer (Waltham, MA). All other reagents, including fluorescently 
labeled oligonucleotides, were purchased from Sigma-Aldrich (St. Louis, MO) and used 
without further purification. Six- to eight-week-old BALB/c female mice were purchased 
from Charles River Laboratories (Wilmington, MA). All work performed on animals was in 
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accordance with and approved by the University of North Carolina Institutional Animal Care 
and Use Committee.
2.2. Preparation and Characterization of Fully-PEGylated LCP Nanoparticles
LCPs were prepared using a modified protocol.12,22 Briefly, two, 5 mL 3:7 Igepal co-520/
cyclohexane w/o microemulsions were prepared: one with 150 μL of dibasic ammonium 
phosphate (50 mM) and the other with 150 μL of calcium chloride (2.5 M) (with or without 
soluble therapeutic). Emulsions were stirred for 10 min, mixed together, and stirred for an 
additional 10 min, followed by addition of 62.5 μL of DOPA (35 mM). After an additional 
30 min of stirring, the mixture was washed repeatedly with absolute ethanol under 
centrifugation (10 000g) to yield a precipitate purified from the excess surfactants. The 
precipitate was then resuspended in chloroform and centrifuged once more (10 000g) to 
purify the DOPA-coated calcium phosphate (CaP) cores (supernatant) from more poorly 
formed nanoprecipitates (pellet). Encapsulation was characterized radiometrically using a 
gamma counter (the Nucleus, Oak Ridge, TN) or through a fluorescence method.
CaP cores were then mixed with a slight (2.5-fold) excess of outer-leaflet lipids in 
chloroform, dried into a thin, transparent film under nitrogen, and resuspended at 65 °C 
under aqueous conditions (beginning with absolute ethanol and titrating to <20% with 
additional DI water). Molar ratios of outer-leaflet lipids for the traditional LCP formulation 
follow as 2:2:1 DOTAP/cholesterol/DSPE-PEG. Zeta potential and particle size were 
measured using a Malvern ZetaSizer Nano Series (Westborough, MA). TEM images of both 
DOPA-coated CaP cores and fully-PEGylated LCP liposomes were acquired using a JEOL 
100CX II TEM (JEOL, Japan), the latter of which was stained with uranyl acetate (UA).
For surface composition analysis, LCP purification was performed via sucrose density 
gradient centrifugation. Briefly, in a centrifuge tube, layers of varying sucrose concentration 
(40%, 20%, 10%, and 0%) were prepared, with nanoparticle solution comprising the top 
layer. Nanoparticles were labeled at the level of the core (177Lu) and either the inner leaflet 
(0.3% NBD-OPA) or the outer leaflet (1% NBD-OPC or 1% DSPE-PEG-FITC). Samples 
were centrifuged using a swinging bucket rotor (60 000 rpm, 4 h, 4 °C), and visible 
fluorescent signal under UV illumination, which penetrated into the lower sucrose layers, 
was recovered. Such fractions were analyzed fluorometrically to determine the percentage of 
input fluorescence recovered (through either the CaP core preparation for NBD-OPA or the 
density gradient centrifugation for the NBD-OPC or DSPE-PEG-FITC) and normalized 
radiometrically to core content.
2.3. Pharmacokinetics and Biodistribution of Fully-PEGylated LCP Nanoparticles
BALB/c mice were injected intravenously (via tail vein) or subcutaneously (local to the right 
inguinal lymph node) with nanoparticle suspensions (supplemented with 5% glucose to 
balance osmolarity). For kinetics studies, blood samples were extracted serially via tail clip, 
with the final time point obtained via cardiac puncture. For studies in tumor-bearing mice, 
orthotopic 4T1 tumors were produced in BALB/c mice through subcutaneous inoculation of 
2 × 105 cells at the mammary fat pad and grown under monitoring over the following 8–10 
days. Organ harvest was conducted at 6, 24, 48, or 72 h postinjection, depending on the 
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kinetic longevity of the nanoparticles in question; all solid organs were rinsed with PBS and 
dried with lab tissues before weighing. Blood samples and whole organ extracts were 
characterized radiometrically using a gamma counter.
2.4. Hepatic Uptake of Fluorescence-Labeled Oligonucleotides Delivered by Fully-
PEGylated LCP
Fully-PEGylated LCP nanoparticles encapsulating Texas Red-labeled oligonucleotides were 
injected intravenously in 5% glucose to balance osmolarity. After 12 h, livers were harvested 
and fixed in formalin overnight, hydrated in PBS containing 30% sucrose, and frozen in 
OCT (Tissue-Tek, Dublin, OH). Ten micron tissue sections were generated and mounted 
onto Superfrost Plus slides (Fisher Scientific, Houston, TX). Tissue sections were rinsed 
with PBS and mounted in DAPI-containing medium; actin staining was facilitated prior to 
addition of mounting medium via FITC-phalloidin staining and subsequent washing with 
PBS. Images were acquired with a Nikon Eclipse Ti fluorescence microscope.
2.5. Statistical Analysis
Data are presented as mean ± SD. Statistical significance was defined by P < 0.05 through a 
two-tailed t test when comparing two groups and the Holm-Sidak test for multiple 
comparisons.
3. RESULTS AND DISCUSSION
3.1. LCP Nanoparticles Coated Exclusively by PEGylated Phospholipids: Preparation, 
Characterization, and Surface Density Analysis
Lipid-coated nanoparticle (CaP) cores have proven to be an effective formulation 
mechanism for drug encapsulation and delivery, in particular for a variety of nucleic acid 
and phosphorylated peptide and prodrug therapies which are limited in formulation within 
traditional liposomes.15,21,23 Unique to such CaP cores is the dense coating of DOPA on the 
calcium phosphate nanoparticle surface, which is underscored by the maintenance of such 
high-density particles (theoretical specific activity of ~1.6) in suspension in chloroform 
under high separation forces (centrifugation at 10 000g). Previous methods for generating an 
outer lipid layer on such CaP cores employed a mixed lipid system comprising traditional 
bilayer-forming lipids such as DOPC and DOTAP, helper lipids such as cholesterol, and the 
antifouling polymer–lipid conjugate DSPE-PEG2000; within such a thermodynamic system, 
PEG density on the nanoparticle surface has been shown to plateau at roughly 20 mol % of 
total outer lipid.12 However, CaP core coating exclusively with PEGylated phospholipids has 
yet to be explored. Herein, we present such liposomes for the first time, coating nanoparticle 
cores ranging from 10 to 15 nm in diameter (Figure 1B) exclusively with DSPE-PEG2000 to 
produce a well-dispersed population of around 30 nm (Figures 1A,B and S1B). Such 
particles represent only minor degrees of aggregation, as observed instead through a volume-
averaged distribution (Figure 1A) as well as a visually transparent final product compared to 
traditional 20 mol %-PEGylated LCP (Figure 1C). Most notable for this fully-PEGylated 
formulation is the ease with which one can resuspend such nanoparticles from a transparent 
thin film containing DSPE-PEG2000 through simple addition of fresh, absolute ethanol 
followed by rapid dilution with DI water, avoiding the high-energy and comparatively scale-
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limited disruptive methods (i.e., sonication) of deaggregation typically employed for the 
traditional 20 mol %-PEGylated LCP formulation at comparable outer leaflet excesses. 
Further, such exclusive phospho-lipopolymer coatings can be formed with a variety of 
PEGylation chain lengths (Figure S1A) and CaP core sizes (Figure S1B) through the 
inclusion of cholesterol in the formulation.
Traditional bilayer-forming lipids such as DOPA (under deionized conditions) or DOPC, 
when assembled into a lipid bilayer structure, possess headgroup cross-sectional areas 
(CSA) on the sub-nm2 level.24 Further, a headgroup CSA in great excess of that of the acyl 
chains will drive micellar formulation in aqueous suspension, as in the case of DSPE-PEG 
alone, preventing the full PEGylation of a traditional liposome possessing an aqueous core. 
Given the stability of our CaP cores in suspension under high separation forces and our 
ability to formulate CaP cores exclusively on the outer leaflet with DSPE-PEG, we desired 
to characterize the lipid packing density on the surface of the calcium phosphate 
precipitates, in terms of proposed inner leaflet and outer leaflet. Given the obvious 
thermodynamic discrepancies between traditional liposomes and LCP, as well as the 
significant reduction in size of our formulations with regard to the capabilities of traditional 
liposomes, our goals herein were limited to ascertaining whether DOPA within the inner 
leaflet and/or DSPE-PEG2000 on the outer leaflet organizes on the surface of the calcium 
phosphate cores in a density commensurate with traditional bilayer-forming lipids. To 
characterize these nanoparticles at each level of the formulation, we expanded upon an 
established protocol of density-gradient centrifugation,12 utilizing the following components 
for quantitation: 177Lu, a radionuclide whose solubility product equilibrium favors 
encapsulation within the CaP core; NBD-OPA, a fluorescent lipid used in small proportions 
to ascertain the DOPA content on the surface of the CaP core; NBD-OPC, a fluorescent 
analogue of DOPC which functions similarly for outer leaflet quantitation; and DSPE-
PEG2000-FITC. Thus, at each level of the particle (core, inner leaflet, outer leaflet, PEG 
corona), we possess a means by which to characterize the particles after purification under 
sucrose density gradient, wherein the nanoparticles accumulate as a narrow band (Figure 
S1B) and can be harvested and analyzed both radiometrically and fluorometrically. Table 1 
summarizes these measurements based on the fractional densities of both calcium phosphate 
and oleic acid within the 12 nm CaP cores (Figure 1B). Therein, we observe PA, PC, and PE 
headgroup CSA on the subnm2 level, which suggests a density of lipid packing 
commensurate with traditional bilayer formation for both traditional LCP as well as its fully-
PEGylated counterpart, despite working with a nanoparticle for which the aqueous core 
analogue (a liposome approximately 20 nm in diameter) would be entirely unstable. These 
data represent the first determination of lipid packing density for the LCP system as well.
Such results may at first glance seem surprising for a bilayer system which exclusively 
incorporates DSPE-PEG on the outer leaflet, as they suggest a relatively high density of 
PEG (1.3 PEG chains per nm2) on a spontaneously organized surface. However, the high 
aspect ratio of such nanoparticle cores (~10 nm) must be emphasized in this formulation in 
comparison to traditional liposomal formulations such as Doxil (~100 nm). As the PEG 
corona occupies a majority of the total volume of the fully-PEGylated LCP, one can clearly 
envision the multiple-fold increases in free volume as one expands outward radially, along 
with the underlying entropic benefits. Thus, at the distal ends of the PEG corona on these 
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PEGylated LCP nanoparticles (a 5–10 nm radial expansion as observed by DLS and a 
relatively conservative benchmark for a brush-conforming PEGylation density), one can 
easily consider a far less densely packed polymer system, particularly where entropic benefit 
is most easily accessible for the polymer chains. Moreover, this expansion of free volume is 
most evident when considering the larger CaP cores (Figure S1B), which cannot be 
resuspended effectively without the presence of a lesser proportion of cholesterol (2:1 PEG/
chol). Larger cores of 30–40 nm CaP diameter possess far less of an increase in aspect ratio 
as one expands outward radially; thus, cholesterol, which possesses non-negligible surface 
area occupancy in its own right within the bilayer, serves to expand the initial free volume 
occupied by the PEG chains and support entropic gains at the level of the lipid bilayer rather 
than at the PEG corona. Further studies to thoroughly characterize the lipid character on 
such nanoparticles remain necessary; however, a bilayer organization of lipids represents the 
most reasonable interpretation of the LCP nanoparticle surface.
3.2. Kinetics and Biodistribution of Fully-PEGylated LCP after Intravenous Injection
Our motivation to increase further the density of PEG on the LCP nanoparticle surface 
initiated in part from previous work with traditional LCP, which showed a surprisingly rapid 
distribution clearance, only exhibiting extended circulation longevity after well over half of 
the injected dose had been eliminated from the circulation.12,15 Further, the LCP 
nanoparticle system, in particular due to the novelty in establishing a supported lipid bilayer 
on the surface of a solid CaP nanoparticle core, has been shown to open up a variety of 
therapeutics (nucleic acids,10,13,15 phosphorylated peptides,21 and small-molecule 
prodrugs13) to unilamellar liposomal delivery and efficacy in vivo which are exceedingly 
difficult to load passively within the aqueous core environment of a traditional liposome 
(e.g., Doxil). Given our particles’ increased PEGylation density on the outer leaflet, as well 
as the improved quality of the formulation (particularly without extensive excesses of outer 
leaflet lipids or extreme formulation conditions such as sonication), we hypothesized that we 
would be able to reduce such rapid distribution clearance and increase the overall systemic 
exposure to our fully-PEGylated formulation. Further, we sought to broaden our efforts in 
exploring the impact of PEG chain length on circulation longevity at such unprecedented 
liposomal PEGylation density. After injection via tail vein, BALB/c mice were sampled 
serially for blood at various time points and sacrificed for whole-organ biodistribution 
analysis after sufficient clearance from the circulation. Figure 2A highlights such chain 
length dependencies on circulation longevity, showing therein a proportional relationship. 
While LCP coated exclusively with PEG350 phospholipids was rapidly cleared from the 
circulation, upon extension of the chain to PEG1000, a two-phase distribution profile 
emerged. Further extension to PEG2000 decreased both the distribution and elimination 
clearance rates as well, with PEG5000 allowing for only a negligible increase in overall 
exposure. Further, such increases in kinetic longevity (a mean residence time of 13 h for the 
PEG2000 formulation) correlate as expected to the extent of protein adsorption to the 
nanoparticles (Figure S2A), which is readily anticipated given the marked differences 
between such formulations in their ability to effectively screen liposome surface charge from 
the surrounding environment (Table S1). Further, such fully-PEGylated LCP nanoparticles 
encapsulating both model drug (dsDNA oligos) and 177Lu almost fully abrogate the 
distribution clearance which 20 mol % PEG2000-modified LCP possesses, particularly under 
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low-energy resuspension conditions, increasing the overall systemic exposure to the 
nanoparticles (Figure S2B). In contrast to previously published data as well,15 targeting to 
the asialoglycoprotein (ASGPR) receptor on hepatocytes through galactose ligands 
(conjugated to the distal chain end of PEG) contributed to an increased distribution clearance 
without entirely abrogating nanoparticle long-circulating properties. Further, CaP core size 
does not meaningfully impact nanoparticle circulation or biodistribution properties (Figure 
S2C).
These dependencies on chain length and targeting express themselves further through the 
terminal biodistribution profiles of such fully-PEGylated particles (Figure 2B). As one 
increases PEG chain length from 350 to 1000 to 2000 Da, dramatic changes in their overall 
distribution to major organs of nanoparticle clearance are apparent. Given their instability in 
physiological salt and serum conditions due to their failure at effective liposome surface 
charge screening, PEG350-modified LCP exhibits an extensive distribution to the liver, where 
over half of the injected radionuclide accumulates. While PEG1000-modified LCP shows a 
prolonged clearance and an enhanced evasion of uptake within the liver, splenic 
accumulation predominates at a surprising 304% ID per gram tissue; however, such 
phenomena of dramatic splenic nanoparticle accumulation is not entirely unexpected as one 
progresses into the long-circulation domain.25 It is sufficient, however, at the level of 
PEG2000 modification for LCP to effectively evade uptake in all major clearing organs, 
instead accumulating in bone at anywhere from 10% to 25% ID per gram in our sampling 
due to the natural tropism for free Lu to accumulate therein (such high accumulation, 
extended across the entire skeletal system, corresponds to roughly half of the injected 177Lu 
dose). To confirm this evaluation mechanistically, galactose-PEG2000-modified LCP resolves 
much of the loss of 177Lu in this manner, refocusing the nanoparticles more specifically to 
the liver (~50% ID/g), on par with the traditional LCP formulation15 through active targeting 
(in contrast to the passive scavenging of the poorly shielded PEG350 formulation by the 
liver). In essence, this natural bone tropism for our radionuclide tracer serves a dual benefit 
of tracking a truly particle-specific distribution while also providing means through which to 
quantitatively characterize such particles’ stealth properties, given the ability for LCP 
modified with increasing PEG chain length to avoid uptake within traditional organs of 
nanoparticle clearance. The PEG5000 formulation functioned similarly to the PEG2000 
formulation, with minor accumulation differences potentially owing a causal relationship to 
the well-considered PEG shedding phenomenon, whereby over extended in vivo exposure 
lipids with an increased ratio between PEG and acyl chain length will shed such chains at an 
increased rate, thus opening up such particles to opsonization and immune scavenging 
despite long-circulating benefits.3,26 Further, our supported bilayer platform provides a 
mechanism by which to fully PEGylate the outer leaflet utilizing macromolecular materials 
which would self-organize into micelles under any alternative conditions of spontaneous 
self-assembly. Thus, our LCP platform can be confirmed to support a functional outer leaflet 
independent of phyisco-chemical considerations which drive traditional liposome and 
polymersome formation.
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3.3. Hepatic Distribution of Fully-PEGylated LCP after Intravenous Injection
Given such improved circulation properties and enhanced stealth supported by such fully-
PEGylated liposomes, we sought to explore the means through which such a particle system 
may support favorable distribution to a variety of therapeutic targets in vivo; namely, both 
primary hepatocytes and solid tumors via systemic delivery and local as well as systemic 
lymphatics upon subcutaneous administration. In the case of the former, previous studies 
utilizing LCP PEGylated to low densities (0–20 mol %) presented a surprising phenomenon 
which was found to be independent of active targeting: the dramatic alteration in the passive 
distribution of such nanoparticles locally within the liver, showing a shift in tropism with 
increased PEGylation density beyond 10 mol % from Kupffer cells, the resident 
macrophages of the liver, to uptake within the primary hepatocytes.12 We thus sought to 
explore whether a fully-PEGylated LCP nanoparticle, delivering a Texas Red-labeled 
oligonucleotide, could extend this phenomenon absent any traditional bilayer-forming lipids 
or active targeting strategies. Mice were sacrificed at 12 h postinjection (after extensive 
clearance of the nanoparticles from the circulation), and livers were harvested, fixed, 
sectioned, and stained with both DAPI (blue) and FITC-phalloidin (green) for visualization 
of nucleus and cytoskeleton, respectively. Indeed, through fluorescence imaging of these 
frozen liver sections (Figure 3), we observe a notable delivery of Texas Red-labeled dsDNA 
oligo through the fully-PEGylated formulation; further, such distribution is represented as a 
diffuse red fluorescence across the hepatocellular substructures, indicating an effective 
escape of such oligonucleotides from endosomes after internalization. Thus, LCP 
nanoparticles coated exclusively on their outer leaflet by DSPE-PEG2000 can also facilitate 
comparably hepatocyte-specific delivery at the intraorgan level, extending the phenomenon 
observed through traditional LCP.
3.4. Accumulation of Fully-PEGylated LCP upon Local and Systemic Administration within 
Local and Systemic Lymphatics and Solid Tumors
Next, we sought to explore the potential for such particles in delivery both locally and 
systemically toward more complex targets. With complete PEGylation of the outer leaflet in 
our novel formulation, we anticipated an improved lymphatic drainage and accumulation 
over time upon subcutaneous administration,23 as a logical extension of phenomena 
observed in traditional liposomal PEGylation27 as well as alternative particle systems such 
as dendrimers (which in particular exhibit a decreased systemic and increased lymphatic 
distribution with both an increase in particle size and PEGylation).28 Therefore, BALB/c 
mice were injected s.c. with either 100 or 20 mol % PEGylated particles in a 5% glucose 
solution, each targeted with 20% of the total DSPE-PEG2000 functionalized as mannose-
modified DSPE-PEG2000, and major organs were harvested after 6 and 24 h to characterize 
particle accumulation therein. Though systemic kinetic absorption was not detectable for 
such formulations, accumulation for the fully-PEGylated (PCP) (Figure 4) within the 
draining lymph node was increased over 6-fold (970% vs 150% ID per gram tissue). 
However, the fully-PEGylated yet untargeted formulation exhibited significant accumulation 
within systemic lymphatics (specifically, within the contralateral lymph node to the injection 
site), implying meaningful absorption characteristics absent local internalization. Therefore, 
to compare with the glucose-balanced particles, we instead prepared an osmotically 
balanced preparation in 10% sucrose, intended for the inhibition of clathrin-mediated 
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endocytosis local to the injection site. Indeed, we can observe dramatic absorption of both 
formulations within the systemic circulation in this capacity, a recapitulation of the 
lymphatic accumulation contralateral to the injection site, and a consistent maintenance of 
the differential accumulation within the draining inguinal lymph node between 20 and 100 
mol % PEGylated formulations (Figure S3), emphasizing the impact of targeting on particle 
distribution in vivo. Further, such fully-PEGylated particles remain amenable to 
internalization into an immortalized dendritic cell line (JAWSII) to improved degrees to that 
of 20 mol % PEGylated LCP (Figure S5). Therefore, such exclusively PEGylated 
nanoparticles represent an improved delivery system for accumulation in local lymphatics 
upon subcutaneous administration.
Similarly, such a prolonged distribution phase and stealth property for the fully-PEGylated 
formulation would be expected to benefit accumulation within solid tumors via systemic 
administration, in part through the well-characterized enhanced permeability and retention 
(EPR) effect.6 BALB/c mice were inoculated with 4T1 cells orthotopically at the mammary 
fat pad, where after 8–10 days tumors varying in size around 100 mm3 were formed. Mice 
were then injected i.v. with PCP or LCP particles, either unmodified or incorporating 20% 
DSPE-PEG2000-AA, in a 5% glucose solution, with blood and major organs harvested 24 h 
postinjection. Overall PCP nanoparticle distribution within the host as well as to solid tumor 
remained unaffected by targeting and produced a particle-specific distribution profile 
representing accumulation within tumors (~10–12% ID/g) on par with hepatic and splenic 
accumulation (~15–30% ID/g) (Figure 5). While LCP nanoparticles displayed only a modest 
difference in their accumulation within tumors (~5% ID/g), the dramatic accumulation of 
such nanoparticles within the liver and spleen (~60% and 150% ID/g, respectively) 
underscores the value which PCP provides in its stealth property, as can be observed in the 
accumulation ratios between tumor and either liver or spleen. Further, PCP particles again 
remain amenable to internalization to improved degrees to that of traditional LCP (Figure 
S5). Therefore, such fully-PEGylated nanoparticles also represent an effective delivery 
system for accumulation within solid tumors upon intravenous administration. In each of 
these cases of local and systemic delivery, we are currently evaluating the therapeutic 
efficacy of these fully-PEGylated liposomes and plan to include such findings in a later 
publication.
4. CONCLUSIONS
In this work, we present for the first time a liposome based on the lipid-coated calcium 
phosphate (CaP) core platform of diverse sizes (10–15 nm, 30–40 nm) that is coated on the 
outer leaflet exclusively by PEGylated phospholipids of varying polymer chain length (350–
5000 Da). Such LCP particles exhibit improved circulation longevity and immune-evasive 
properties in a chain length-dependent manner, while facilitating both strong accumulation 
within solid tumors upon intravenous injection and a more rapid and extensive lymphatic 
drainage upon subcutaneous administration. Further, these fully-PEGylated LCP particles 
remain amenable to active targeting strategies which elicit improved degrees of focused 
distribution and nanoparticle uptake, represent an outer leaflet surface density commensurate 
with the formation of a lipid bilayer, and avoid harsh physical resuspension processes which 
are necessary for preparation of traditional LCP nanoparticles. We anticipate that such 
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improved delivery properties can translate into improved therapeutic safety and efficacy for 
a variety of systemic and lymphatic diseases.
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LCP coated exclusively by PEGylated phospholipids. LCP cores were rehydrated from a 
clear, transparent thin film under high ethanol conditions, with optimal resuspension 
occurring with fresh absolute ethanol at 65 °C, followed by rapid dilution with deionized 
water. TEM images (B) and DLS measurements (A) convey a well-dispersed and highly 
transparent CaP core population in comparison to traditional LCP (20 mol % PEGylation, 
(C)). UA = uranyl acetate. Scale bar = 50 nm.
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Kinetics and biodistribution of fully-PEGylated LCP liposomes exhibits chain length-
dependent stealth properties. CaP precipitates encapsulating trace amounts of 177Lu were 
modified exclusively with PEGylated phospholipids (DSPE) of varying chain length and 
targeting capabilities and administered via tail vein to BALB/c mice (n = 4), with kinetics 
(A) monitored radiometrically through serial sampling and biodistribution (B) similarly after 
organ harvest. PEG-GAL: ASGPR-targeted PEG2000.
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Primary hepatocyte targeting through a fully-PEGylated LCP. DSPE-PEG2k-modified LCP 
encapsulating oligonucleotides labeled with Texas Red were administered via tail vein. 
Twelve hours later, BALB/c mouse livers were harvested and frozen sections were prepared 
for imaging. Green = FITC-phalloidin stain. Blue = DAPI. Images: 0.125 mg/kg Texas Red 
oligo without (A) and with (C) actin stain, and untreated mouse livers without (B) and with 
(D) actin stain. Scale bar = 100 μm.
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LCP biodistribution upon subcutaneous administration. LCP particles encapsulating 
trace 177Lu were coated with either 100 mol % (PCP) or 20 mol % (LCP) DSPE-PEG2k and 
administered subcutaneously to BALB/c mice in 5% glucose (n = 3). Major organs were 
harvested at various time points, and nanoparticle accumulation was determined 
radiometrically. C = contralateral; I = ipsilateral (local to injection site). MAN = mannose 
targeting. *p < 0.05; **p < 0.01.
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LCP biodistribution in tumor-bearing mice. BALB/c mice were inoculated orthotopically 
with 4T1 tumors, and biodistribution of fully-PEGylated (PCP) and traditional (LCP) 
formulations containing trace 177Lu was determined at 24 h post-tail vein injection. Average 
tumor size = 100 mm3 (n = 3–4). *p < 0.02 vs LCP-AA.
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Table 1
Determination of PEG Density on LCP Liposomesa
CaP cores per batch (#/mL oil phase) 1014 PC headgroup CSA (nm2) 0.8
core density (theor.) (mg/mm3) 1.6 PE headgroup CSA (nm2) 0.8
core DOPA recovery (molout/molin) 35% PEG chains/nm2 (lipid bilayer) 1.3
PA headgroup CSA (nm2) 0.6 PEG chains/nm2 (PEG corona, est.) 0.2
a
LCP nanoparticles comprising cores encapsulating 177Lu, coated with either 20 or 100 mol % DSPE-PEG2k, and incorporating trace amounts of 
NBD-OPA, NBD-OPC, or DSPE-PEG-FITC were purified via sucrose gradient centrifugation and quantified via established fluorescence and 
radiometric methods.
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